Skip to Content

Frequently Searched

Supported by

Perspectives: Published Editorials and Industry Updates

Welcome to Perspectives, our blog designed to keep members, oncology stakeholders, and anyone interested in enhancing the care experience for oncology patients informed on critical issues. You’ll hear from thought leaders and learn about the impact and benefits of medically integrated pharmacy, operational insights designed to support you in the day-to-day delivery of care, as well as timely industry issues facing oncology pharmacy professionals.

SORT

Celebrating a Decade of Impact: Member Spotlight on Andrew Ruplin, PharmD

As NCODA marks 10 years of advancing patient-centered oncology care, we’re spotlighting the members who make a difference every day. Meet Andrew Ruplin, PharmD of Fred Hutchinson Cancer Center and UW Medicine, whose dedication to patients and passion for innovation exemplify what it means to be part of the NCODA community. Read his story in our latest member spotlight.

Best Practices for Patient Management in Veteran Health

Cancer care within the Veterans Health Administration (VHA) is shaped by a unique patient population that requires integrated, evidence-based approaches. Veterans often have complex health histories, mental health concerns, and social barriers to care. These challenges demand not only medical expertise, but also a system of care that acknowledges the lived experiences and sacrifices of those who served.

Serving Those Who Served: Delivering Oncology Care to Veterans

What does oncology care look like within the VA system—and how does it differ from the private sector? We recently sat down with former VA oncology pharmacist Nigina Ali, PharmD, to explore how care teams support Veterans through cancer treatment, the unique challenges they face, and the systems in place to meet their needs. Her firsthand insights shed light on both the strengths and the hurdles of delivering high-quality cancer care to those who served.

NCODA Perspective: Protecting Access to Oncology-Optimized Limited Distribution Drugs 

June 26, 2025
Access to oncology-optimized limited distribution (OOLD) drugs is being increasingly threatened by shifting pharmacy benefit manager (PBM) practices that divert prescriptions away from medically integrated pharmacies (MIPs). NCODA is working with stakeholders to defend MIP access and safeguard oncology patients’ treatment journeys.

Coming Soon: Important OCE/IVE Updates

OCE and IVE sheets will soon be known as Patient Education Sheets — clearer, more consistent, and still rooted in the expert-backed information you rely on.

NCODA Announces “Oncology Optimized Limited Distribution” to Bring Clarity and Enhance Patient-Centered Cancer Care Delivery 

May 14, 2025
Cazenovia, New York, May 14, 2025 – During the recent NCODA International Spring Forum, the organization announced the formal definition of Oncology Optimized Limited Distribution (OOLD) to bring clarity to the broadly used term “limited distribution networks “(LDNs), within the oncology ecosystem. This effort supports the improved delivery of oral oncolytics and enhances patient outcomes by promoting medically integrated pharmacy models whenever possible. 

NCODA AT 10 

April 22, 2025
This article is about the founding and evolution of NCODA, sparked by the growing need for better oral oncolytic care, and how the organization has continued to adapt, innovate, and stay true to its patient-centered, collaborative mission over the past decade.